In this episode, TRC Healthcare editor, Rachel Cole, PharmD, evaluates 3 new migraine treatments: Atzumi, Brekiya, and Symbravo. She'll explain their dosing techniques and how they compare to existing therapies, while providing practical guidance on clinical considerations and cost-effective alternatives for acute migraine management.

This is an excerpt from our August 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Stay Up to Date on “New” Migraine Meds
• Chart: Drugs for Acute Migraine
• Chart: Migraine Prophylaxis
• FAQ: Medication Overuse Headache

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new or upgraded subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.